Tag: ado-trastuzumab emtansine

August 2026 was a busy month for the antibody-drug conjugate (ADC) field, with activity spanning the full arc of development. Highlights included early discovery partnerships, manufacturing alliances, a practice-changing phase 3 readout in lung cancer, and the first dosing of a novel Treg-depleting ADC.

Clinical Study finds ADCs to be Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...

The U.S. Food & Drug Administration (FDA) has accepted Byondis' submission of a Biologics License Application (BLA) for trastuzumab duocarmazine (previously known as...

In the mid-1970s, scientists discovered that certain genes, when mutated, can cause cancer.  Based on this observation they theorized that by targeting these oncogenes,...

The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...

Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed signs of clinical activity of...

International Nonproprietary Names (INN) Ado-trastuzumab emtansine Prescription Drug Yes Class Antineoplastic Agents US Brand Name Kadcyla® Other names ado-trastuzumab emtansine, trastuzumab-DM1, T-DM1 Available as a generic drug No Marketing Authorization Genentech/Roche United States Adopted Name (USAN) Trastuzumab...